LEVI & KORSINSKY, LLP: BONE MINERAL DENSITY CLAIMS CHALLENGED IN MEREO BIOPHARMA SECURITIES ACTION
LEVI & KORSINSKY, LLP: BONE MINERAL DENSITY CLAIMS CHALLENGED IN MEREO BIOPHARMA SECURITIES ACTION |
| [18-March-2026] |
Time-Sensitive: Allegations Focus on BMD-to-Fracture Reduction Representations NEW YORK, March 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP alerts investors in Mereo BioPharma Group plc (NASDAQ: MREO) to a pending securities class action. The Court has set April 6, 2026 as the deadline to apply for lead plaintiff appointment.
"Investors deserve transparency about material risks that could affect their investments," stated Joseph E. Levi, Esq., managing partner of Levi & Korsinsky, LLP. "The translation of bone mineral density improvements to actual fracture reduction is a fundamental issue for biopharmaceutical investors."
Submit your information to join this case or contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com | (212) 363-7500. The Alleged BMD-Fracture Correlation Problem The lawsuit asserts that management repeatedly claimed setrusumab's ability to increase bone mineral density would necessarily translate to reduced fracture rates in OI patients. As alleged, the Company touted Phase 2 data showing a "67% reduction in annualized fracture rate" while omitting that this data lacked the control group comparisons necessary to establish causation. What Management Allegedly Knew The action claims that despite public expressions of confidence, management possessed information suggesting the Phase 3 trials faced significant challenges. It is alleged that executives were aware the Phase 2 results could not properly distinguish setrusumab's effects from improvements due to increased standard of care or placebo effects. Industry Context for OI Drug Development
Why BMD Adequacy Allegedly Matters to Investors According to the action, the fundamental question for investors was whether BMD improvements constituted a reliable surrogate endpoint for fracture reduction. The complaint alleges that while the Company consistently achieved BMD improvements, these did not translate to the clinically meaningful fracture reduction the market expected. Speak with an attorney about your options WHY LEVI & KORSINSKY, LLP Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, Levi & Korsinsky, LLP is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors across the country. CONTACT:
SOURCE Levi & Korsinsky, LLP | ||
Company Codes: NASDAQ:MREO,NASDAQ-NMS:MREO |
View original content to download multimedia:
